看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。- P* ?( j$ O$ U( q3 y. a9 m8 q
# t1 B7 Y" q' ]
# F3 f8 m0 ], ^) c6 w4 H, T* V6 o
Currently available feasibility data for possible combination strategies. 5 n7 }- P' v# D# {, K7 p" B
————————————————————————————————
" U# Z5 ^( f3 T4 m' W. `9 @Combination Feasibility according to preliminary data
$ q7 p/ ^0 B' t. x2 t2 |——————————————————————————————————3 I7 m* q, S4 H' ?* O( d* K
Bevacizumab + sorafenib Yes, reduced dose ) _, u3 R; B- b6 c0 q
Bevacizumab + sunitinib† No
0 S" R) z' O" B- ^2 c2 i7 pBevacizumab + temsirolimus Yes & H3 o2 ~8 Z4 k7 n; l! q& ^
Bevacizumab + everolimus Yes : h9 r! S2 s) ~# J
Sorafenib + sunitinib ? ; w/ S2 _1 A. u$ ^! P5 h
Sorafenib + temsirolimus Yes, reduced dose % G5 f' q' ^3 X I+ ]0 C" w
Sorafenib + everolimus Yes, reduced dose 1 t8 }! d" n2 |4 I; n B! _( i1 R
Sunitinib + temsirolimus† No
W2 z o$ ~" ]% I- SSunitinib + everolimus ? 5 p1 r' j0 @1 \8 Z6 _) l/ U: d' G
Temsirolimus + everolimus ? 8 m. M6 S1 ^4 E; ?% i+ h
————————————————————' B8 E2 b ]+ h; X% U3 ^ G
†Led to US FDA warning.% `7 e+ K5 w3 Q1 F. K- i5 Q7 S
?: As yet unattempted combination.! @0 S. ?8 Y! Z; ^/ n2 U' [
|